ALEXIS BOURGEOIS: Open Payments
NPI 1346873403 · FRANKLIN, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,226 in 48 payments from 18 companies in 2025. Trend: 2023 $460 · 2024 $171 · 2025 $1,226
Food & beverage: $1,226
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $304 |
| ABBVIE INC. | 15 | $198 |
| Alkermes, Inc. | 7 | $182 |
| Vanda Pharmaceuticals Inc. | 2 | $131 |
| Tarsus Pharmaceuticals, Inc. | 1 | $98 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Lundbeck LLC | 1 | $28 |
| Braeburn Inc. | 1 | $26 |
| Corium, LLC | 2 | $26 |
Products named: VRAYLAR, UZEDY, FANAPT, AUSTEDO XR, XDEMVY, ARISTADA, LYBALVI, REXULTI.
Industry payments across LA — which companies pay providers there.
